QURE – uniQure N.V.
Float Short %
19.96
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.59
EPS Last/This Y
1.57
EPS This/Next Y
0.58
Price
23.47
Target Price
50.5
Analyst Recom
1.43
Performance Q
-21.14
Upside
-512.2%
Beta
0.66
Ticker: QURE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | QURE | 25.12 | 0.19 | 0.09 | 124972 |
| 2026-01-26 | QURE | 25.39 | 0.18 | 0.14 | 131936 |
| 2026-01-27 | QURE | 24.36 | 0.19 | 1.17 | 133135 |
| 2026-01-28 | QURE | 23 | 0.19 | 0.15 | 134070 |
| 2026-01-29 | QURE | 23.64 | 0.19 | 0.15 | 135197 |
| 2026-01-30 | QURE | 22.71 | 0.19 | 0.40 | 137314 |
| 2026-02-02 | QURE | 24.72 | 0.19 | 0.16 | 138096 |
| 2026-02-03 | QURE | 27.8 | 0.18 | 0.09 | 150362 |
| 2026-02-05 | QURE | 24.54 | 0.19 | 0.07 | 163862 |
| 2026-02-09 | QURE | 26.03 | 0.20 | 0.41 | 171054 |
| 2026-02-10 | QURE | 24.69 | 0.21 | 0.69 | 172178 |
| 2026-02-11 | QURE | 24.14 | 0.22 | 0.07 | 174216 |
| 2026-02-12 | QURE | 22.38 | 0.21 | 0.25 | 176702 |
| 2026-02-13 | QURE | 20.51 | 0.22 | 0.40 | 177638 |
| 2026-02-17 | QURE | 21.73 | 0.22 | 0.17 | 179573 |
| 2026-02-18 | QURE | 23.43 | 0.22 | 0.44 | 181913 |
| 2026-02-19 | QURE | 24.42 | 0.22 | 0.95 | 189452 |
| 2026-02-20 | QURE | 23.47 | 0.23 | 0.86 | 190936 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | QURE | 25.09 | 45.2 | -0.5 | -3.35 |
| 2026-01-26 | QURE | 25.24 | 45.2 | 23.5 | -3.35 |
| 2026-01-27 | QURE | 24.35 | 45.3 | 33.2 | -3.35 |
| 2026-01-28 | QURE | 23.02 | 45.3 | 37.9 | -3.35 |
| 2026-01-29 | QURE | 23.67 | 45.3 | 17.7 | -3.35 |
| 2026-01-30 | QURE | 22.72 | 44.9 | 34.6 | -3.35 |
| 2026-02-02 | QURE | 24.74 | 44.9 | 3.0 | -3.35 |
| 2026-02-03 | QURE | 27.79 | 44.9 | -4.0 | -3.35 |
| 2026-02-04 | QURE | 26.66 | 44.9 | - | -3.35 |
| 2026-02-05 | QURE | 24.55 | 44.9 | - | -3.35 |
| 2026-02-06 | QURE | 25.66 | 44.9 | - | -3.35 |
| 2026-02-09 | QURE | 26.05 | 44.9 | - | -3.35 |
| 2026-02-10 | QURE | 24.74 | 44.9 | - | -3.35 |
| 2026-02-11 | QURE | 24.14 | 44.9 | - | -3.35 |
| 2026-02-12 | QURE | 22.42 | 45.0 | - | -3.35 |
| 2026-02-13 | QURE | 20.50 | 45.0 | - | -3.35 |
| 2026-02-17 | QURE | 21.75 | 45.0 | - | -3.35 |
| 2026-02-18 | QURE | 23.43 | 45.0 | - | -3.35 |
| 2026-02-19 | QURE | 24.42 | 45.0 | - | -3.35 |
| 2026-02-20 | QURE | 23.47 | 45.0 | - | -3.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | QURE | -6.72 | 3.32 | 21.12 |
| 2026-01-26 | QURE | -6.72 | 4.20 | 21.12 |
| 2026-01-27 | QURE | -6.72 | 4.20 | 21.12 |
| 2026-01-28 | QURE | -6.72 | 4.20 | 20.37 |
| 2026-01-29 | QURE | -6.72 | 4.20 | 20.37 |
| 2026-01-30 | QURE | -6.72 | 4.20 | 20.37 |
| 2026-02-02 | QURE | -6.72 | 4.19 | 20.37 |
| 2026-02-03 | QURE | -6.72 | 4.19 | 20.37 |
| 2026-02-04 | QURE | -6.72 | 4.19 | 20.37 |
| 2026-02-05 | QURE | -6.72 | 4.19 | 20.37 |
| 2026-02-06 | QURE | -6.72 | 4.19 | 20.37 |
| 2026-02-09 | QURE | -6.72 | 4.61 | 20.37 |
| 2026-02-10 | QURE | -6.72 | 4.61 | 20.37 |
| 2026-02-11 | QURE | -6.72 | 4.61 | 20.07 |
| 2026-02-12 | QURE | -6.72 | 4.61 | 20.07 |
| 2026-02-13 | QURE | -6.72 | 4.61 | 20.07 |
| 2026-02-17 | QURE | -6.72 | 15.82 | 20.04 |
| 2026-02-18 | QURE | -6.82 | 15.82 | 20.04 |
| 2026-02-19 | QURE | -7.15 | 15.82 | 19.96 |
| 2026-02-20 | QURE | -7.15 | 15.82 | 19.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.38
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-0.79
Insider Transactions
-7.15
Institutional Transactions
15.82
Beta
0.66
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
41
Growth Score
32
Sentiment Score
69
Actual DrawDown %
67.2
Max Drawdown 5-Year %
-90.1
Target Price
50.5
P/E
Forward P/E
PEG
P/S
91.64
P/B
6.37
P/Free Cash Flow
EPS
-4.39
Average EPS Est. Cur. Y
-3.35
EPS Next Y. (Est.)
-2.77
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1492.9
Relative Volume
0.71
Return on Equity vs Sector %
-131.8
Return on Equity vs Industry %
-114.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.59
EBIT Estimation
uniQure N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading